Van Beek Jeroen B's Form 4 filing
Kalaris Therapeutics, Inc. (KLRS) · filed Jul 6, 2022
- Accession no.
- 0000899243-22-025233
- Filed
- Jul 6, 2022
- Trade date
- Jun 3-Jul 1, 2022
- Filing delay
- 33 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.87K. It was filed 33 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Van Beek Jeroen BCIK 0001743662 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2022 | Common Stock | SSaleDisposed | −515 | $3.63F2 | −$1,869.45 | 389,011 | Direct | |
| Jul 1, 2022 | Common Stock | AGrant or awardAcquired | +14,000 | $0.00 | $0 | 403,011 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 1, 2022 | Common Stock | AGrant or awardAcquired | +26,000 | $0.00 | $0 | 26,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.60 to $3.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.